Abrahamov, A., Abrahamov, A., & Mechoulam, R. (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sciences, 56(23–24), 2097–2102.
Ahmedzai, S., et al. (1983). Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. British Journal of Cancer, 48(5), 657–663.
Anderson, S. P., et al. (2019). Impact of medical cannabis on patient-reported symptoms for patients with cancer enrolled in Minnesota’s medical cannabis program. Journal of Oncology Practice, 15(4), e338–e345.
Bar-Sela, G., et al. (2020). Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome. Cancers, 12(9), 2447.
Behling-Hess, C., et al. (2025). The impact of cannabis on immune checkpoint inhibitor therapy: A systematic review of immunomodulatory effects of cannabis in patients with and without cancer. Supportive Care in Cancer, 33(3), 166.
Castle, R. D., et al. (2025). Meta-analysis of medical cannabis outcomes and associations with cancer. Frontiers in Oncology, 15, 1490621.
Deandrea, S., et al. (2008). Prevalence of undertreatment in cancer pain: A review of published literature. Annals of Oncology, 19(12), 1985–1991.
Foroughi, M., et al. (2011). Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas—possible role of cannabis inhalation. Child's Nervous System, 27(4), 671–679.
Gastmeier, K., et al. (2024). The use of tetrahydrocannabinol is associated with an increase in survival time in palliative cancer patients: A retrospective multicenter cohort study. Medical Cannabis and Cannabinoids, 7(1), 59–67.
Guzmán, M., et al. (2006). A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. British Journal of Cancer, 95(2), 197–203.
Haroun, R., Wood, J. N., & Sikandar, S. (2023). Mechanisms of cancer pain. Frontiers in Pain Research, 3, 1030899.
Hinz, B., & Ramer, R. (2022). Cannabinoids as anticancer drugs: Current status of preclinical research. British Journal of Cancer, 127(1), 1–13.
Kenyon, J., Liu, W. A. I., & Dalgleish, A. (2018). Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Research, 38(10), 5831–5835.
National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press.
Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011). Regulation of nausea and vomiting by cannabinoids. British Journal of Pharmacology, 163(7), 1411–1422.
Phansila, N., et al. (2025). Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study. F1000Research, 11, 1212.
Pinto, J. S., & Martel, F. (2022). Effects of cannabidiol on appetite and body weight: A systematic review. Clinical Drug Investigation, 42(11), 909–919.
Razmovski-Naumovski, V., Luckett, T., Amgarth-Duff, I., & Agar, M. R. (2022). Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: A systematic review. Palliative Medicine, 36(6), 912–927.
Rock, E. M., et al. (2011). Interaction between non-psychotropic cannabinoids in marihuana: Effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology, 215(3), 505–512.
Rock, E. M., Limebeer, C. L., & Parker, L. A. (2015). Effect of combined doses of Δ9-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat models of conditioned gaping. Psychopharmacology, 232(24), 4445–4454.
Rock, E. M., et al. (2021). Therapeutic potential of cannabidiol, cannabidiolic acid, and cannabidiolic acid methyl ester as treatments for nausea and vomiting. Cannabis and Cannabinoid Research, 6(4), 266–274.
Sallan, S. E., Zinberg, N. E., & Frei, E. (1975). Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England Journal of Medicine, 293(16), 795–797.
Salum, K. C. R., et al. (2025). The endocannabinoid system in cancer biology: A mini-review of mechanisms and therapeutic potential. Oncology Reviews, 19, 1573797.
Schleider, L. B.-L., et al. (2018). Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine, 49, 37–43.
Singh, Y., & Bali, C. (2013). Cannabis extract treatment for terminal acute lymphoblastic leukemia with a Philadelphia chromosome mutation. Case Reports in Oncology, 6(3), 585–592.
Śledziński, P., et al. (2023). In vitro evidence of selective pro-apoptotic action of pure cannabidiol and cannabidiol-rich extract. Molecules, 28(23), 7887.
Sulé-Suso, J., et al. (2019). Striking lung cancer response to self-administration of cannabidiol: A case report and literature review. SAGE Open Medical Case Reports, 7, 2050313X19832160.
Taha, T., et al. (2019). Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. The Oncologist, 24(4), 549–554.
Thomas, J., et al. (1982). Cannabis and cancer chemotherapy: A comparison of oral delta-9-THC and prochlorperazine. Cancer, 50(4), 636–645.
Twelves, C., et al. (2021). A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer, 124(8), 1379–1387.
Velasco, G., Sánchez, C., & Guzmán, M. (2016). Anticancer mechanisms of cannabinoids. Current Oncology, 23(Suppl 2), S23.
Waissengrin, B., et al. (2023). The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief? European Journal of Cancer, 180, 52–61.
